基于母血单细胞测序的无创筛查胎儿致病性微失衡并与侵入性产前诊断比较
这项前瞻性多中心队列研究纳入1390例接受侵入性产前诊断的高危孕妇,在孕11+0至22+6周采集母血分离循环绒毛外滋养细胞进行单细胞全基因组测序。该方法对≥300 kb至<8 Mb的致病或可能致病拷贝数变异敏感性为92.9%,特异性为98.2%。研究显示该技术对胎儿全基因组微失衡的检测分辨率可与染色体微阵列分析相比。
要点
- 单细胞测序无创产前检测可检出≥300 kb至<8 Mb的胎儿致病性微缺失/微重复。
- 对21三体的敏感性为98.0%,特异性为99.7%。
- 该方法在孕早期可能明显降低传统cfDNA筛查后的残余风险。
核心结论
- 单细胞测序无创产前检测对胎儿全基因组致病或可能致病拷贝数变异具有较高敏感性和特异性,分辨率可与染色体微阵列分析相比。
研究设计与样本
- 在孕11+0至22+6周、侵入性取样前采集20 mL母血,分离循环绒毛外滋养细胞进行全基因组测序。
主要发现
- 对全基因组≥300 kb至<8 Mb微失衡的敏感性为92.9%(95% CI, 76.5-99.1%),特异性为98.2%(95% CI, 97.0-99.0%)。
- 在孕11+0至14+6周筛查时,对≥300 kb致病或可能致病拷贝数变异的敏感性为100%(95% CI, 83.9-100%)。
- 对21三体的敏感性为98.0%(95% CI, 92.9-99.8%),特异性为99.7%(95% CI, 99.0-99.9%)。
关键数值与推荐
- 单细胞测序无创产前检测结果与核型分析和/或染色体微阵列分析的标准侵入性产前诊断结果进行比较。
- 微失衡定义为≥300 kb至<8 Mb的拷贝数变异。
临床怎么用
- 该技术可用于高危孕妇孕早期胎儿全基因组致病性微失衡的无创筛查。
- 可能作为现有cfDNA筛查的补充,用于降低未检出的染色体异常残余风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pathogenic or likely pathogenic copy-number variants (p/lpCNVs) are a significant cause of perinatal morbidity and mortality. Current prenatal screening based on cell-free DNA (cfDNA) fails to detect the majority of microimbalances (microdeletions/microduplications), leaving a significant residual risk of undetected chromosomal abnormalities. This study evaluated the clinical performance of a novel single-cell-sequencing-based non-invasive prenatal testing (scsbNIPT) method utilizing circulating extravillous trophoblasts (cEVTs) for the detection of fetal p/lpCNVs, particularly microimbalances < 8 Mb. METHODS: This was a prospective, blinded, observational multicenter cohort study of 1390 high-risk pregnant women undergoing prenatal invasive diagnostic testing between November 2021 and December 2023. A 20-mL maternal blood sample was collected from each subject between 11 + 0 and 22 + 6 weeks' gestation prior to invasive sampling. cEVTs were isolated and subjected to whole-genome sequencing, using a proprietary workflow. scsbNIPT results were compared with standard invasive prenatal diagnostic results obtained by karyotyping and/or chromosomal microarray analysis. RESULTS: scsbNIPT showed a sensitivity of 92.9% (95% CI, 76.5-99.1%) and a specificity of 98.2% (95% CI, 97.0-99.0%) for the detection of genome-wide microimbalances measuring ≥ 300 kb to < 8 Mb. The sensitivity for p/lpCNVs ≥ 300 kb in pregnancies screened at 11 + 0 to 14 + 6 weeks was 100% (95% CI, 83.9-100%). For trisomy 21, the sensitivity of scsbNIPT was 98.0% (95% CI, 92.9-99.8%) and the specificity was 99.7% (95% CI, 99.0-99.9%). CONCLUSIONS: This study demonstrates the scientific validity and clinical utility of scsbNIPT for the non-invasive detection of genome-wide fetal p/lpCNVs, particularly microimbalances, with high sensitivity and a resolution comparable to that of chromosomal microarray analysis. scsbNIPT may offer more complete screening for genome-wide p/lpCNVs, markedly lowering the residual risk early in pregnancy compared with existing cfDNA-based methods. © 2026 Menarini Silicon Biosystems. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Stampalija, Forcato, Grati, et al. Single-cell-based non-invasive screening for fetal pathogenic microimbalances using maternal blood: comparison with invasive prenatal diagnosis. Ultrasound Obstet Gynecol. 2026. PMID: 41883021. doi:10.1002/uog.70201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。